DCISionRT by PreludeDx Identifies Women with DCIS with Unacceptably High Rates of Local Recurrence after Breast Conserving Surgery and Radiation Therapy
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the...
Source: prnewswire.com